Ocrelizumab OverviewOcrelizumab (trade name Ocrevus) is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds. It was approved by the FDA in March 2017 as a treatment for multiple sclerosis, and the first FDA approved drug for the primary progressive form of MS; it was discovered and developed and is marketed...
Read more Ocrelizumab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ocrelizumab
Recent Ocrelizumab Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 30mg/1ml